Aging impairs organismal homeostasis leading to multiple pathologies. Yet, the mechanisms
and molecular intermediates involved are largely unknown. Here, we report that aged aryl …

Cellular senescence is traditionally considered as stable cell cycle arrest state with other
phenotypic alterations including the production of an array of cytokines and growth factors …

Over 70% of breast cancers express the estrogen receptor (ER) and depend on ER activity
for survival and proliferation. While hormone therapies that target receptor activity are …

Inducing senescence in cancer cells is emerging as a new therapeutic strategy. In order to
find ways to enhance senescence induction by palbociclib, a CDK4/6 inhibitor approved for …

Background: Breast cancer has traditionally been considered to have a low immunogenic
potential compared to other tumor entities. Summary: The most extensively studied …

Simple Summary Breast cancer cells travel via the bloodstream to the bone before the
cancer is detectable in the breast. These disseminated cells are resistant to adjuvant …

Palbociclib is the first CDK4/6 inhibitor approved by FDA and has been studied in many
types of cancer. However, some studies showed that it could induce epithelial …

Despite significant advances in targeted therapies against the hyperactivated
BRAFV600/MEK pathway for patients with unresectable metastatic melanoma, acquired …

Melanoma is one of the most aggressive solid tumors and includes a stromal
microenvironment that regulates cancer growth and progression. The components of stromal …

Cellular senescence has been increasingly recognized as a hallmark of cancer, reflecting its
association with aging and inflammation, its role as a response to deregulated proliferation …